logo-loader
Polarean Imaging PLC

Polarean Imaging signs deal with University of British Colombia

CEO Richard Hullihen said: “UBC has a long history and pioneering reputation in the field of medical imaging research and I look forward to providing further updates regarding our collaboration with UBC as appropriate.”

1550218265_shutterstock_703970935.jpg
The company is a specialist in medical imaging

Polarean Imaging Plc (LON:POLX), the medical imaging technology company, said the University of British Columbia (UBC) is acquiring one of the company’s polarizer systems.

No financial details were mentioned, but the Polarean release said UBC has received support from the Canada Foundation for Innovation.

The company’s chief executive, Richard Hullihen, said: "We are excited to welcome Doctors Sin and Leipsic and the staff of UBC to our expanding base of collaborative researchers and look forward to assisting them in achieving the goals of their research programme.

“UBC has a long history and pioneering reputation in the field of medical imaging research and I look forward to providing further updates regarding our collaboration with UBC as appropriate.”

Quick facts: Polarean Imaging PLC

Price: £0.24

Market: AIM
Market Cap: £27.64 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Polarean Imaging PLC named herein, including the promotion by the Company of Polarean Imaging PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Polarean Imaging begins enrolment for phase III clinical...

Polarean Imaging PLC's (LON:POLX) Richard Hullihen tells Proactive London's Andrew Scott they're on track to complete recruitment to their phase III clinical trial by the end of the current quarter following the enrolment of the first patient at the third site. The company’s drug-device...

2 weeks, 3 days ago

RNS

Phase III Clinical Trials update

2 weeks, 4 days ago

Total Voting Rights

3 weeks, 2 days ago

Holding(s) in Company

3 weeks, 3 days ago

Holding(s) in Company

3 weeks, 3 days ago

Holding(s) in Company

3 weeks, 4 days ago

Result of AGM

4 weeks, 1 day ago

Exercise of Warrants

4 weeks, 2 days ago

2 min read